In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Mendaera has found a leader with deep medical robotics experience to lead its commercialization push. Eric Davidson has taken ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Havas is forging deeper into the GLP-1 space with a series of YouTube videos about the drug class and its impact on the world ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Following a fresh round of job cuts in December, CDMO National Resilience is carrying its downsizing efforts into 2025. | ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Anthem Biosciences, an India-based CDMO, submitted a filing (PDF) at the end of 2024 to announce its plans for a 33.95 ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...